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Abstract
The study of hepatitis C virus (HCV) genotypes/subtypes, quasispecies and recombinants obtained by virus genome
sequencing are important for epidemiological studies, to trace the source of infection, for development of new
direct acting antivirals (DAAs) therapy and for understanding antiviral selection pressures. The HCV NS5B gene
encodes a polymerase, which is responsible for virus replication and is a potential target for the development of
antiviral agents. Many studies for classification of HCV use a particular segment of the NS5B gene, in addition to
other specific regions, and phylogenetic analysis. Actually, some nucleoside/nucleotide analogues and non-
nucleoside inhibitors target NS5B protein. This review focuses on HCV variability, phylogenetic analysis and the role
of NS5B in the virus-host interactions.
Introduction
Hepatitis C virus (HCV) is classified as the type member
of the genus Hepacivirus within the family Flaviviridae
[1,2]. Nucleotide sequencing allows us to classify HCV
into seven genotypes and many subtypes, epidemiologi-
cally related to risk factors and geographical areas [3].
HCV genotype determines the duration of antiviral
therapy and predicts the response to treatment [4]. In
particular viral genotypes influence clinical outcome not
only to interferon (IFN)-based therapies but also to IFN
free regimens. Classification of HCV into genotypes and
subtypes detected by commercial assays is commonly
satisfactory to reach a clinical choice. Moreover, the typ-
ing of HCV variants, as well as knowledge of the genetic
diversity, is important for epidemiological studies such as
those to trace the source of infection [5,6].
Phylogenetic and phylogeographical analysis have
recently been applied to study the molecular epidemiol-
ogy of HCV [7-9]. Interestingly, investigation of the spa-
tial and temporal distribution of HCV diversity is
critical not only to provide information on the virus ori-
gin and history, unknown prior to its identification, but
also for understanding mechanism of virus-host interac-
tion, and for preventive strategies [10,3].
Several studies reported heterogeneity in the regions
sequenced along the HCV genome, such as 5’-UTR,
core, NS5B, HVR-1, E2 and a segment of the NS5A
gene associated with interferon sensitivity (ISDR) [11].
Guidelines for classification of genotypes/subtypes, using
either the entire genome or the core/E1 and NS5B
regions of HCV have been proposed [12,2]. In particu-
lar, a segment of the NS5B gene, identifying genomic
polymorphisms, has been used [12,2]. HCV NS5B, an
RNA dependent RNA polymerase (RdRp), has been stu-
died in various biochemical assays, cell based assays and
animal model systems. NS5B variability could be asso-
ciated with a worse prognosis of the disease, as demon-
strated for D310N substitution in HCV 3a infected
patients [13].
The aim of the present review is to present the cur-
rent knowledge of HCV variability for the critical role of
NS5B in virus-host interaction.
NS5B polymerase
Virological aspects
The viral polymerase NS5B (full-length protein 591 amino
acids, aa) synthesizes a complementary negative strand
RNA using as template genomic positive strand RNA. The
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catalytic domain, formed by N-terminal 530 aa, exhibits
the classical “fingers”, “palm” and “thumb” subdomains
typically seen in all RNA dependent RNA polymerases.
The active site of NS5B is fully encircled by the fingers
and thumb domains, which closely interact. All regular
structures, studied until now, reveal a closed conforma-
tion, encircled on one side by the fingertips and on the
other side by the linker and the so-called b-hairpin. There-
fore, the active site is fully enclosed and the nucleotide
molecules can bind easily with no further rearrangement
of the domains [14,15]. As observed in in vitro studies,
NS5B is able to conduct a template-directed RNA synth-
esis on its own, requiring only divalent metals (magnesium
or manganese) as cofactors. NS5B can also catalyze both
de novo synthesis from a single-stranded template and pri-
mer extension from the subsequent RNA duplex or from
a pre-annealed template/primer duplex [16].
HCV RNA replicates in close association with intracel-
lular membranes, so infected cells contain vesicles form-
ing a membranous web (MW) that can be the HCV
replication site [17].
Romero-Brey et al. [18], in 2012, carried out an investiga-
tion on the 3D morphology and biogenesis of the intracel-
lular membrane structures induced by HCV. The
architecture of the membrane alterations induced by HCV
reveals unexpected similarities between HCV and the unre-
lated picorna- and coronaviruses. Therefore, HCV induces,
early during an infection, double membrane vesicles
(DMVs), which emerge as protrusions of the endoplasmic
reticulum (ER). Later on, HCV triggers multi-membrane
vesicles (MMVs) that are probably the result of a cellular
stress reaction [18]. Consequently, morphology of the MW
depends not only on RNA replication, but also on activity
of the nonstructural proteins NS3- NS5B, in concert with
cellular factors [15]. Indeed, host factors such as lipid kinase
phosphatidylinositol 4-kinase III alpha (PI4KIIIa) are essen-
tial for RNA replication and interact with NS5B and NS5A
proteins. Silencing of PI4KIIIa reduces vesicles formation,
suggesting that this enzyme is critically involved in web
morphology and consequently in viral replication [19,20].
Pathogenetical aspects
NS5B binds to several cellular proteins. In particular, it
directly interacts with pRb (retinoblastoma - susceptibil-
ity protein). The pRb-binding site of NS5B partially
overlaps with its polymerase active site and then RdRp
activity is blocked. Interaction occurs in both replicon
and HCV-infected cells and induces ubiquitination and
subsequent degradation of pRb, probably contributing to
the oncogenic property of HCV [21].
Liver cirrhosis and hepatocellular carcinoma induced by
HCV may involve the interplay of different host cell fac-
tors, as well as interaction of these factors with viral RNA
and proteins. Upadhyay et al. [22], using an affinity capture
system in conjunction with liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS),
showed that three viral proteins, NS5B, NS5A and NS3/
4A helicase are associated with replicating positive strand
RNA genome in hepatoma cells. Moreover, 83 cellular fac-
tors such as translation factors, ribosomal proteins,
and metabolic enzymes have been found to be associated
with HCV genomic RNA. In particular the chaperonin
T-complex polypeptide (TCP1), participates in HCV RNA
replication and virion production, possibly through its
interaction with NS5B. Moreover Caprin 1, a cell-cycle
associated phosphoprotein, forms a complex with Ras-
GTPase-activating protein-binding protein 1 (G3BP1)
which has been shown to interact with both HCV NS5B
and the 5’ end of the HCV minus-strand RNA indicating
that it is part of HCV replication complex [22].
In vitro models are important to study viral functional
adaptation in human hosts and the natural course of infec-
tion [23]. An improvement was achieved after the cloning
of a genotype 2a isolates from a Japanese patient with ful-
minant hepatitis (JFH 1 strain). Intra- and inter-genotypic
chimeras, derived from the JFH1 strain, have also been
constructed, allowing comparative studies between differ-
ent genotypes/subtypes [24].
Characterization of JFH1 chimeric genome suggested a
role for NS5B during viral assembly [25]. Authors gener-
ated a JFH1 chimeric genome, encoding an amantadine-
sensitive p7 protein, and identified two point mutations in
NS2 and NS5B, which restored the infectivity of defective
chimeric genomes. This finding disclosed an association
among NS2, NS5B and p7 during virus morphogenesis
[25].
Therapeutical aspects
NS5B represented, over the past decade, a therapeutic tar-
get for the inhibition of viral replication. Indeed, the new
findings on viral replication, as well as close correlation
between viral and host factors, make, even now, the poly-
merase a good therapeutic target. In addition, two first
approved protease inhibitors show a low genetic barrier,
inducing rapid onset of drug resistance. Actually, the resis-
tance profiles of DAAs observed in clinical trials are
strongly discussed.
Noteworthy alternative drugs are represented by nucleo-
side/nucleotide analogues, such as sofosbuvir, and non-
nucleoside inhibitors, such as BI-207127, both of them
directed to NS5B. Currently, sofosbuvir may be associated
with ribavirin as therapy for HCV 2 or HCV 3 and with
NS5A inhibitors for other genotypes. In HCV genotypes
1 and 4 infection, sofosbuvir/RBV/PEG-IFN may be given
for 12 weeks. In persons with HCV 1 infection, IFN
intolerant, sofosbuvir/RBV may be given for 24 weeks
[26]. BI-207127 is in Phase III development in combina-
tion with ribavirin and an NS3 protease inhibitor [27].
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Recently a replicon-based reagent suitable for conveni-
ent investigation of small molecule-mediated inhibition
of HCV genotype 3 NS5A and NS5B has been generated
and validated. This replicon chimera represents a useful
tool to further study properties/behaviors of polymerase
in different HCV genotypes [28].
HCV variability
Virological aspects
The positive strand of RNA genome is about 9600
nucleotides long and contains an open reading frame
(ORF) encoding polyprotein precursor. The polyprotein
is processed into structural and nonstructural proteins
by host cell signal peptidases and two viral proteases
(NS2 and NS3/4A) [14]. High HCV replication rate,
such as 1012 virions per day, and the absence of proof-
reading activity of NS5B polymerase are the main fac-
tors that contribute to mutations in the viral genome.
Genome variation is characterized by close genetic
diversity among the viruses circulating in an infected
host. As a result, HCV exists as a quasispecies [29].
HCV polymerase NS5B is responsible of the error
mechanism of the gene products. In agreement with its
functional role during the viral life cycle, there are few
data on diversity within the HCV polymerase.
Recombination, which is an important evolutionary
process, is uncommon during the HCV life cycle,
although HCV type co-infections are recognized and
recombination among genotypes would be expected
[30]. Viral recombination has been demonstrated during
HCV infection [31] and recently re-examined [32] in
view of the low probability to detect recombinant strains
and considering the potential underestimation of their
incidence.
Viral variants have an impact on immunologic escape
and/or antiviral drug resistance and the latter is particu-
larly important in the DAAs (direct acting antivirals)
era, when drugs act directly on the specific viral protein.
Di Maio et. al [33] analyzed the NS5B polymerase varia-
bility in circulating HCV genotypes/subtypes and its
impact on the genetic barrier for the development of
resistance to clinically relevant nucleoside inhibitors
(NIs)/non-nucleoside inhibitors (NNIs).
Pathogenetical aspects
Blackard et al. [34] detected NS5B intrapatient variabil-
ity by a greater median genetic distance in the HIV/
HCV-coinfected women than in the HCV-monoinfected
women. Since HCV RNA levels appear to be signifi-
cantly increased during HIV/HCV coinfection and HIV
coinfection is associated with a reduced drug therapy
response, authors conclude that HIV can affect NS5B
variability. This is intriguing as this suggests the host
immune system, compromised by HIV, can influence
genetic diversity of HCV. Functional characterization of
unique NS5B sequences, identified in vivo, could demon-
strate how NS5B variability influences viral replication
fitness [34].
Therapeutical aspects
The effect of NS5B heterogeneity on the activity of
nucleoside and non-nucleoside HCV polymerase inhibi-
tors was investigated in clinical isolates obtained from
serum samples of treatment-naive patients. It has been
shown that non- nucleos(t)ide resistance mutations are
present in the viral population at a low frequency in their
quasispecies and these variants can be promptly selected
upon drug pressure [35]. In particular, three major NNI
resistant variants (414T, 419S, and 422K) were associated
with a different genetic barrier score development among
the six HCV genotypes. HCV NS5B sequencing could
help to provide efficacy of NNI-containing regimens [33].
Blackard et al. [34] assessed serum NS5B variability in a
subset of genotype 1-infected women, which included
both HIV/HCV coinfected and HCV monoinfected
patients, demonstrated a link between NS5B viral diver-
sity and viral load that could influence therapy outcomes.
Among the partial NS5B consensus sequences generated,
21 of 114 (18.4%) amino acid positions were variable.
Moreover, recombination could implement antiviral
resistances because two different mutations could be
brought together a viral recombination event [32].
Phylogenetic analysis
Epidemiological aspects
The epidemiology of HCV infection is rapidly changing
and HCV prevalence rates between and within countries
is characterized by local variability. Risk factors and gen-
otype distribution also have significant geographic and
temporal differences. Sequence variability analysis is
important for molecular epidemiological studies and for
understanding the endemic or epidemic origin of HCV
infection. Furthermore, HCV epidemic subtypes show
high prevalence, low genetic diversity, and spreading dur-
ing the 20th century via blood transfusions, injecting drug
use and invasive medical procedures. On the contrary,
endemic subtypes reveal long persistence in human
populations in geographically restricted areas, with low
transmission rates and a high genetic diversity as a result
[36-38].
Epidemiological changes of HCV infection in Europe,
such as in Italy, have been identified. In particular,
human migration was responsible for early genotypes/
subtypes distribution and actually remains an important
factor in HCV type spreading [39].
In 2012, our group investigated the phylogeny of HCV
subtype 4d isolated from Italian patients in Calabria
(Southern Italy) by analyzing a fragment of the NS5B
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viral genomic region. A Bayesian coalescent-based frame-
work was used to assess origin and spread of the HCV 4d
in this area. Phylogenetic analysis indicated that genotype
4 circulated in Calabria region with a predominance of
subtype 4d. Moreover, the Italian 4d isolates shared a
common ancestor with reference 4d isolates whose origin
was traced back to 1940s (1913-1968). This finding sug-
gests that spread of genotype 4d probably began during
the Second World War by immigration from Africa [8].
To assign an accurate genotype/subtype and to iden-
tify a new type, sequences of NS5B genomic region and
phylogenetic analysis that reconstructed HCV spreading
are required [40,5].
In 2002, Richter reported that the NS5B region is the
“gold standard” for accurate subtyping [41]. In the same
year, Kalinina et al. isolated the first recombinant HCV
strain. These authors identified an inter-genotype
recombinant between a subtype 2k and a subtype 1b. In
this study, the recombinant forms (RFs) were detected
performing phylogenetic analysis on 5’ UTR-core and
NS5B regions [31].
Du et al. [42] detected firstly HCV 3a/1b recombinant
through discrepancy of core/E2 and NS5B fragments
sequences. HCV recombination and dual infection are
often associated with high-risk multiple exposure beha-
viors. Detection of 3a/1b dual infection not only sup-
ports the existence of HCV 3a/1b recombinant, but also
indicates a possibility of on-going generation of HCV
inter-subtype recombinants [42].
Pathogenetical aspects
Genetic characterization of animal homologs of human
viruses gives information on HCV natural history, evolu-
tion and preventive and therapeutic interventions.
Kapoor et al. [10], reported the significant finding of
HCV homologous non-primate virus. Phylogenetic analy-
sis of conserved regions in NS3 and NS5B genes of
rodent virus demonstrated homologous sequences with
human viruses. The homology allows to hypothesize a
zoonotic source of infection and suggests development of
new animal models useful to investigate HCV pathogen-
esis and treatment. In particular, comparative genetic
analysis and functional characterization studies might
reveal host specificity determinants and different tissue
tropism [10]. Extrahepatic replication of HCV in periph-
eral blood mononuclear cells (PBMC) has significant
implications for disease progression and treatment out-
come. However, few data are available concerning HCV
variability in extrahepatic sites. Blackard et al. [43], by
phylogenetic analysis of NS5B and E1/HVR1 sequences,
evaluated quasispecies extrahepatic diversity by assessing
NS5B variability in serum and PBMC samples from
chronic HCV patients. Moreover, they identified the
possible compartmentalization in PBMCs of HCV
variants. Adaptive evolution of non-structural genomic
regions such as NS5B could contribute to HCV persis-
tence [43].
Therapeutical aspects
Pickett et al. [44], in 2011, identified a statistically signif-
icant evolutionary divergence of subtype 1a HCV iso-
lates into two distinct clades with potentially different
phenotypic behaviors that may reflect differences in
treatment response. The informative sites distinguishing
clade 1 from clade 2 are distributed throughout the gen-
ome, but are mainly located in the E1, E2, NS2, NS5A,
and NS5B coding regions. In particular, one site within
the 5′ UTR and several sites within the NS5B genotyp-
ing fragments differ between clades 1 and 2, this infor-
mation could be helpful to known if clades differ for
therapy resistance. Furthermore, several variants are
located at codons associated with resistance to protease
inhibitors (NS3 Q41) or polymerase inhibitors (NS5B
S368) [44].
Conclusions
Since HCV was isolated, there has been an increase in
the number of studies to analyze the virus.
Structural and functional studies of the Hepatitis C
virus RNA dependent RNA polymerase have contributed
to our understanding of polymerase mechanism, viral
RNA replication, and have generated targets for antiviral
development. A multidisciplinary approach which could
yield significant benefits to society against a disease with
enormous worldwide impact is necessary. Major
advances and future research questions on NS5B poly-
merase are reported in Table 1.
Nucleotide sequencing with phylogenetic analysis of
NS5B genomic region, in addition to core/E1, is recom-
mended for HCV genotyping [2]. Interestingly, the dis-
crepancy of genotyping results between core/E2 and
NS5B regions, indicates the presence of a HCV inter-
subtype recombinant [42].
NS5B region alone may be ineffective to identify HCV
recombinants. The heterogeneity of the sequencing
regions, in different publications, suggests a necessary
standardization of regions analyzed for phylogenetics,
phylodynamics and evolutionary studies.
Moreover, viral protein NS5B is a target for thera-
peutic intervention. The DAA molecules, either alone
or in combination with peg-IFN plus RBV, were
recently described as showing large antiviral effects.
DAA monotherapy results in rapid emergence of resis-
tant strains and DAAs must be used in combinations.
The goal of the future studies will be to generate wild
type and mutant (intra or inter-genotypes) replicons to
investigate emergence and fitness of resistance for
NS5B inhibitors.
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